Last year in the UK over 60,000 cancer patients enrolled on clinical trials aimed at improving cancer treatments and making them available to all.
A trial looking at magnetic resonance spectroscopy (MRS) to help diagnose and treat children and young people with brain stem tumours (CNS 2004 11)
This trial looked at magnetic resonance spectroscopy (MRS) scans to see if they could help diagnose brain stem tumours in children and young people.
Magnetic resonance imaging (MRI) scans are used to help diagnose brain stem tumours in children. They are also used to see how well treatment is working. They can tell the doctors where in the brain the tumour is, and how big it is. But MRI scans don’t give the doctors all the information they would like.
Magnetic resonance spectroscopy (MRS) scans are similar to MRI scans, but can give extra information. Earlier trials suggested that the MRS scans may be able to give information about the type of brain tumour, how quickly it is growing and whether certain treatments will work. The doctors running this trial wanted to find out more about this.
The aim of this study was to collect information from MRS scans to increase understanding about the diagnosis and treatment of brain stem tumours in children and young people.
Summary of results
The research team found that MRS scans could be useful to help diagnose brain stem tumours in children and young people.
This trial recruited 35 children with brain stem tumours from 4 hospitals. They all had MRI scans and MRS scans.
The results showed that MRS scans did help to diagnose different types of brain tumours in some people. And there were some differences between the levels of certain substances (called metabolites) in different types of brain tumours. These could help doctors decide whether tumours are likely to grow slowly (low grade tumours) or more quickly (high grade tumours).
The research team concluded that MRS scans could be useful alongside MRI scans to give more information about brain tumours and how well treatments are likely to work.
We have based this summary on information from the team who ran the trial. As far as we are aware, the information they sent us has not been reviewed independently (
How to join a clinical trial
Prof Andrew Peet
Cancer Research UK
Children's Cancer and Leukaemia Group (CCLG)
Department of Health
Engineering and Physical Sciences Research Council (EPSRC)
Medical Research Council (MRC)
NIHR Clinical Research Network: Cancer